ECM Therapeutics, Inc. has licensed multiple extracellular matrix (ECM) technologies developed in the laboratory of Stephen Badylak (pictured) at the McGowan Institute for Regenerative Medicine, including hydrogels, bioactive derivatives and methods for delivering these materials within the body.
The Pittsburgh based company will initially develop EsophaGel™, an ECM hydrogel for the treatment of Barrett's Esophagus which is often a precursor to esophageal cancer. EsophaGel has been shown in pre-clinical studies to halt and possibly reverse the progression of esophageal cancer.
"We are pleased to license this portfolio of patents and patent applications to a startup company based in the Pittsburgh region," said Alex Ducruet, director for licensing and intellectual property in Pitt's Innovation Institute. "Dr. Badylak is one of Pitt's most prolific innovators, and we look forward to the positive impact that these regenerative medicine technologies will have on people's lives."
ECM Therapeutics was founded by Badylak and business development colleague Katie Collins. Badylak lab members Jenna Dziki and George Hussey and the University of Pittsburgh hold equity in the company.